Entecavir for the treatment of chronic hepatitis B. (Q35964745)

11 August 2017

1 reference

title

Entecavir for the treatment of chronic hepatitis B. (English)

1 reference

11 August 2017

1 reference

1 reference

Tim Shaw

1

1 reference

11 August 2017

Stephen Locarnini

series ordinal

2

1 reference

11 August 2017

language of work or name

1 reference

1 December 2004

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

published in

1 reference

11 August 2017

volume

2

1 reference

11 August 2017

issue

6

1 reference

11 August 2017

page(s)

853-871

1 reference

Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

New treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Molecular virology of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

The hepatitis B virus and common mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Genomic analysis of the host response to hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Occult hepatitis B virus infection and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Thymalfasin for the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Cytokine gene polymorphisms in patients infected with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Treatment with interferons (including pegylated interferons) in patients with hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Clinical trial results and treatment resistance with lamivudine in hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Entecavir: a potent new antiviral drug for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Carbocyclic nucleosides (carbanucleosides) as new therapeutic leads

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Synthesis of novel (2R,4R)- and (2S,4S)-iso dideoxynucleosides with exocyclic methylene as potential antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Antiviral guanosine analogs as substrates for deoxyguanosine kinase: implications for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

DNA polymerase gamma, the mitochondrial replicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

21 January 2018

Telomeres and telomerase

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Rapid production of neutralizing antibody leads to transient hepadnavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

Combination chemotherapy for hepatitis B virus: the path forward?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

BMS-200475, a novel carbocyclic 2′-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14789072.2.6.853

21 January 2018

Identifiers

DOI

10.1586/14789072.2.6.853

1 reference

release_pscttubouvhojas5cykfborvou

11 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pscttubouvhojas5cykfborvou

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference